Patent intelligence · US
US 8426597
Nitrate derivatives of cilostazol for the treatment of vascular and metabolic diseases
Nitrate derivatives of cilostazol for the treatment of vascular and metabolic diseases
Patent details — US 8426597
- Jurisdiction
- US
- Status
- granted
- Grant date
- Apr 23, 2013
- Expiration
- Apr 18, 2033
- Applicant
- CARDIOLYNX AG
- Claims
- 14
- CPC classes
- A61P, A61P3/00, A61P3/06, A61P9/00
Quick answer
US 8426597 (Nitrate derivatives of cilostazol for the treatment of vascular and metabolic diseases) is held by CARDIOLYNX AG. Status: granted. Granted Apr 23, 2013. Expires Apr 18, 2033 (7 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- CARDIOLYNX AG
- Grant date
- Expiration
- Claims
- 14
- CPC classes
- A61P, A61P3/00, A61P3/06, A61P9/00, A61P9/10, A61P9/12
More from CARDIOLYNX AG
Related pharmaceutical patents in our USPTO index.
-
US 12419888
Methods of treating elevated plasma cholesterol
granted -
US 11844771
Methods of treating acute respiratory distress syndrome using colchicine
granted -
US 11795434
Engineered stem cells and cellular products produced and secreted by such cells, methods of preparing, and uses thereof
granted -
US 11639490
Device and method for producing and purifying exosomes
granted -
US 11529390
PCSK9 inhibitory polypolypeptides and methods of use
granted -
US 11400063
Early administration of low-dose colchicine after myocardial infarction
granted -
US 10788490
Dried cellulose-treated tissue for in-vitro complement activation assays and diagnostic kits
granted -
US 9789134
Agent for the selective adjustment of blood lipids
granted
Frequently asked questions
What is US patent 8426597?
US 8426597 (Nitrate derivatives of cilostazol for the treatment of vascular and metabolic diseases) is held by CARDIOLYNX AG. Status: granted. Granted Apr 23, 2013. Expires Apr 18, 2033 (7 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 8426597?
CARDIOLYNX AG is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 15 pharmaceutical patents for this assignee.
When does US 8426597 expire?
Our index shows an expiration date of Apr 18, 2033 (7 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.